VIR-2482 

VIR-2482 is a monoclonal antibody targeting influenza A hemagglutinin (HA). VIR-2482 is generated by introducing LS mutations (M428L/N434S) into the Fc region of MEDI8852 (HY-P991446). VIR-2482 binds to the conserved HA stem epitope across all 18 influenza A HA subtypes, neutralizes a broad spectrum of H1N1 and H3N2 strains, binds to FcγRIIIa, FcγRIIa and C1q, and induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. VIR-2482 reduces morbidity and mortality caused by seasonal influenza A strains and provides prophylactic protection in mice. VIR-2482 can be used in research related to influenza A disease^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

VIR-2482 shows that influenza A virus isolates from study participants retain susceptibility to it in vitro, with fold changes in EC₅₀ ranging from 0.23 to 2.55 relative to subtype reference strains^[1].
VIR-2482 binds to all 18 influenza A HA subtypes and neutralizes a broad panel of H1N1 and H3N2 viruses spanning nearly 100 years of evolution, with key contact residues showing >98.8% conservation in H1N1 and H3N2 sequences from 2009-2019^[2].
VIR-2482 retains the ability to engage human FcγRIIIa, FcγRIIa, and C1q, and maintains functional ADCC and CDC activity in vitro despite containing half-life extending Fc mutations^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

VIR-2482 (Prophylactic) protects Balb/c mice from lethal infection with H1N1 PR8 and H3N2 HK/68 influenza A viruses^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

C3W5S1

influenza A virus hemagglutinin HA

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tan SK, et al. A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA). Clin Infect Dis. 2024;79(4):1054-1061.

  [2]. Pizzuto M S, et al. 1231. VIR-2482: A potent and broadly neutralizing antibody for the prophylaxis of influenza A illness[C]//Open Forum Infectious Diseases. US: Oxford University Press, 2020, 7(Supplement_1): S635-S636.

  [3]. Plotnik D, et al. A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness. Antimicrob Agents Chemother. 2024;68(4):e0127323.